GGrantIndex
← Leaderboards

Sinisa Dovat

University Of California Los Angeles

$7,191,819
Attributed
$8,201,675
Total exposure
6
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $825.3K · FY200525
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$8,201,675 · 6

By mechanism

R01$7,205,375 · 4
K08$508,680 · 1
K22$487,620 · 1

Top collaborators

Most similar at University Of California Los Angeles

Same institution · by research overlap

Others in their field

Top investigators on “Leukemia

Research focus

LeukemiaGene ExpressionIn VivoTumor Suppressor ProteinsPhosphotransferasesGenesMolecularPathway InteractionsOverexpressionCell ProliferationOncogenicRepressionChildhoodPhosphorylationHigh RiskPediatric PatientsCombined Modality TherapyRegulationGeneticCell CycleAllelesInsightDna BindingIn Vitro

Grant awards (28)

Novel targeted therapy to reduce health disparities in pediatric leukemia$541,022
R01 · FY2025 · CA · contact PI
Novel targeted therapy to reduce health disparities in pediatric leukemia$513,972
R01 · FY2024 · CA · contact PI
Novel targeted therapy to reduce health disparities in pediatric leukemia$541,022
R01 · FY2023 · CA · contact PI
Targeting CK2 oncogenic pathway to overcome drug resistance in high-risk leukemia$353,876
R01 · FY2021 · CA · contact PI
Targeting CRLF2 and Ikaros Alterations to Reduce Health Disparities in Childhood Leukemia$471,419
R01 · FY2020 · CA
Targeting CK2 oncogenic pathway to overcome drug resistance in high-risk leukemia$353,876
R01 · FY2020 · CA · contact PI
Targeting CRLF2 and Ikaros Alterations to Reduce Health Disparities in Childhood Leukemia$349,730
R01 · FY2019 · CA
Targeting CK2 oncogenic pathway to overcome drug resistance in high-risk leukemia$343,259
R01 · FY2019 · CA · contact PI
Administrative Supplement to: Targeting CRLF2 and Ikaros Alterations to Reduce Health Disparities in Childhood Leukemia$102,422
R01 · FY2019 · CA
Targeting CRLF2 and Ikaros Alterations to Reduce Health Disparities in Childhood Leukemia$360,547
R01 · FY2018 · CA
Targeting CK2 oncogenic pathway to overcome drug resistance in high-risk leukemia$353,876
R01 · FY2018 · CA · contact PI
Targeting CRLF2 and Ikaros Alterations to Reduce Health Disparities in Childhood Leukemia$360,547
R01 · FY2017 · CA
Targeting CK2 oncogenic pathway to overcome drug resistance in high-risk leukemia$353,876
R01 · FY2017 · CA · contact PI
Targeting CRLF2 and Ikaros Alterations to Reduce Health Disparities in Childhood Leukemia$375,047
R01 · FY2016 · CA
The Role of Zinc Finger Genes in Leukemogenesis$359,674
R01 · FY2013 · HL · contact PI
The Role of Zinc Finger Genes in Leukemogenesis$377,941
R01 · FY2012 · HL · contact PI
The Role of Zinc Finger Genes in Leukemogenesis$367,370
R01 · FY2011 · HL · contact PI
The Role of Zinc Finger Genes in Leukemogenesis$301,159
R01 · FY2010 · HL · contact PI
The Role of Zinc Finger Genes in Leukemogenesis$57,370
R01 · FY2010 · HL · contact PI
The Role of Zinc Finger Genes in Leukemogenesis$367,370
R01 · FY2009 · HL · contact PI
The Role of Zinc Finger Genes in Cellular Proliferation$162,540
K22 · FY2007 · CA · contact PI
The Role of Zinc Finger Genes in Cellular Proliferation$162,540
K22 · FY2006 · CA · contact PI
The Role of Zinc Finger Genes in Cellular Proliferation$162,540
K22 · FY2005 · CA
THE ROLE OF ZINC FINGER GENES IN HEMATOPOIESIS$124,673
K08 · FY2003 · CA
THE ROLE OF ZINC FINGER GENES IN HEMATOPOIESIS$2,497
K08 · FY2003 · CA
THE ROLE OF ZINC FINGER GENES IN HEMATOPOIESIS$127,170
K08 · FY2002 · CA
THE ROLE OF ZINC FINGER GENES IN HEMATOPOIESIS$127,170
K08 · FY2001 · CA
THE ROLE OF ZINC FINGER GENES IN HEMATOPOIESIS$127,170
K08 · FY2000 · CA